leadf
logo-loader
viewAstraZeneca PLC
(
LSE:AZN
)

AstraZeneca reports failure in COVID-19 antibody trial on people already exposed to virus

The candidate is also being studied as prevention in individuals not already infected, with results yet to be published

AstraZeneca - AstraZeneca reports failure in COVID-19 antibody trial on people already exposed to virus

AstraZeneca PLC (LON:AZN) announced that the trial for a COVID-19 antibody did not meet its primary goal of preventing symptoms in people exposed to the virus.

Participants were 1,121 unvaccinated adults 18 years and over with confirmed exposure to a person with a case of the virus within the previous eight days.

READ: AstraZeneca to appoint new chief financial officer when Alexion acquisition completes

The candidate, AZD7442, reduced the risk of developing symptomatic COVID-19 by 33% compared to placebo, which was not statistically significant.

All participants had a negative antibody test on the day of dosing to exclude prior infection and another swab at a later date to detect potential infection.

The FTSE 100 group is also studying the candidate as prevention in individuals not already infected, with results yet to be published.

In an analysis of people who had a negative test on the day of dosing, AZD7442 reduced the risk of developing symptomatic COVID-19 by 73%.

“While COVID-19 vaccination efforts have been successful, there is still a significant need for prevention and treatment options for certain populations, including those unable to be vaccinated or those who may have an inadequate response to vaccination,” said Myron J. Levin, professor at the University of Colorado School of Medicine and principal investigator on the trial.

Quick facts: AstraZeneca PLC

Follow
LSE:AZN

Price: 8899 GBX

Market Cap: £137.86 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Catenae Innovation to exhibit Skillflow at the UK Construction Week with...

Catenae Innovation PLC (AIM:CTEA, FRA:NZS0)'s (LON:CTEA) Guy Meyer talks to Proactive London’s Katie Pilbeam about exhibiting at the UK Construction Week with Construction Helpline.  It is the UK's largest construction event, taking place at the National Exhibition Centre, Birmingham, from...

30 minutes ago

2 min read